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Metabolic syndrome (MetS) is a common disease and a serious public health problem in developed countries. 
Chronic inflammation plays a key role in MetS. Interleukins 10 and LpR are considered to involve in inflammatory 
state and may be associated with pathogenesis of MetS. Therefore the aim of this study was to determine the rate of 
gene expression of IL-10& LepR genes in peripheral blood mononuclear cells (PBMCs) in MetS compared to 
control subjects. 
Using real-time RT-PCR, the relative amount of mRNA of the IL-10 & LepR in PBMC from 20 patients with MetS 
was determined and compared with those of twenty control healthy subjects. Classical plasma and anthropometric 
parameters that are characteristics of MetS were also assessed.  
While total cholesterol, triglyceride, and fasting blood sugar were significantly higher in MetS patients compared to 
healthy subjects, no significant differences was observed in HDL-C and LDL-C.  
However there was no significant difference in BMI between two studied groups, statistical analysis indicated that 
BMI more than 30 identified as a risk factor for MetS (OR=2.931). Excessive waist circumference was the most 
frequent of MetS components. PBMC IL-10 expression was significantly decreased in MetS versus control subjects 
(fold of change was 0.55±0.09), while LpR expression increased in MetS participants 2.69±0.51. IL-10 expression 
had negative strong correlation with systolic pressure (r=0.46 P=0.03) while positive correlation with waist 
circumferences was observed (r=0.4 P=0.01). Also LepR showed correlation with TC, LDLc and waist 
circumferences in MetS group (r=0.4 P<0.05). 
To our knowledge, this is the first research that investigated IL-10 & LepR expression in PBMCs of MetS subjects. 
We found an increase in LepR and a decrease in IL-10 expression on PBMC of MetS compared to control subjects. 
Study on a larger population and detecting synthesis of these proteins can reveal more details.   




Metabolic syndrome (MetS) (also referred to Syndrome X, Insulin Resistance Syndrome) is one of the major 
public health challenges worldwide that is characterized by clustering of waist circumference, blood 
triglycerides(TG), HDL cholesterol, fasting glucose and blood pressure with different cut-off [1-3]. MetS and its 
components are risk factors which lead to developing cardiovascular disease and type 2 diabetes [3-5]. MetS can 
cause dyslipidemias, prothrombotic and proinflammatory states, ovarian polycystosis and fatty liver disease and 
finally increased CVD-related and all-cause mortality [1,6,7]. MetS affects approximately 25% of the adult 
population in western countries and also increase quickly in young populations [8-10]. The etiology is complex, 
genetic and environmental factors both have important roles [4]. Although it is unknown which components start 
and drive MetS to worsening condition, it is believed that visceral obesity can lead to development of insulin 
resistance, impaired glucose tolerance, hyperglycemia, and type 2 diabetes [11-13]. Adipose tissue as secretory 
organ release variety of molecules referred to adipocytokines [13]. Leptin is proinflammatory adipokine involved in 
different inflammatory diseases [14, 15]. It is produced mainly by fat tissue and is always correlated with BMI and 
is also unusually high in obese individuals [15]. Of course these leptin cannot suppress eating and promote weight 
loss that termed leptin resistance [16]. Leptin also involves in immune and inflammatory responses [17], which is 
mediate by leptin receptor (OB-R) that expressed by many types of immune cells, pancreatic β cells, adipose tissue, 
and muscle [18, 19].  Inflammation is now thought to play a key role in the pathophysiology of MetS [20]. Recent 
10055 
Saidijam et al., 2012 
evidence has shown association between MetS and chronic low-grade inflammation. Moreover inflammation is 
closely related to obesity [2]. Association between leptin receptor, immune system, and MetS is still uncertain. This 
led to the hypothesis that MetS is mediated directly or indirectly by leptin receptor and its effects on immune 
system. Low-grade systemic inflammation is result of unbalanced production of pro-inflammatory and anti-
inflammatory cytokines [21]. IL-10 plays a key role in balance of pro-inflammatory versus anti-inflammatory status 
[22]. The worth of IL-10 as an anti-inflammatory cytokine is shown by a recent study that reports a low-producing 
IL-10 was associated with a higher cardiovascular morbidity and mortality [21]. Also Esposito et al. showed that 
low levels of IL-10 in MetS [23].Another report proves that low IL-10 production capacity is associated with high 
plasma glucose, high HbA1c, type 2 diabetes, and dyslipidemia and also with metabolic syndrome and type 2 
diabetes [24]. In addition, in a report it was detected association between circulating concentrations of leptin and IL-
10 [25]. We hypothesize that leptin receptor and IL-10 may affect on each other. To our knowledge there is no 
report in expression study of IL-10, LpR and their relation in PBMC of MetS patients. Therefore the purpose of the 
present study was to investigate IL-10 and LepR expression in patients with MetS compared with non-MetS and to 
assess a possible correlation between the expression of these genes and parameters of disease.   
 
2. MATERIALS AND METHODS 
 
 Participants 
Twenty patients with metabolic syndrome (MetS) and 20 age matched healthy subjects participated in this 
study. MetS diagnosis was performed according to the modified criteria for MetS from the National Cholesterol 
Education Program-Adult Treatment Panel III (NCEP-ATP III) [26].  Based on this criteria our patients had three or 
more of the following conditions :  a) central obesity (waist circumference > 90 cm); b) high blood pressure ≥ 
130/85 mmHg or documented use of antihypertensive therapy; c) high fasting glucose (≥ 100 mg/dL); d) 
hypertriglyceridemia (≥ 150 mg/dL), and e) decreased high density lipoprotein cholesterol (HDLc) (< 50 mg/dL ).  
Participants with the following conditions were excluded from the study: estro-progesterone or testosterone 
treatment including oral contraceptives; smoking; pregnancy; amenorrhea; polycystic ovarian syndrome. They were 
not affected by chronic illness, nor taking drugs or supplements known to modify the immune system. No subjects 
showed evidence of chronic diseases (hepatic, renal, thyroid, cardiac), smoking, alcohol consumption, or family 
history of cardiovascular disease of early onset, no they were taking drugs. Informed consent was obtained from all 
participants prior to beginning the study and the study was approved by the Hamadan University of Medical 
Sciences ethics committee, the study also conformed to the principles outlined in the Declaration of Helsinki. Each 
participant underwent a baseline visit after an overnight fast. Height, weight, waist circumference and blood 
pressure were measured. 
 Sample collection 
Following an overnight fasting (≥10 h), venous blood samples were collected between 7 and 8 a.m. Samples 
for CBC and gene expression analysis were collected in tubes containing 1 g EDTA/L. Serum was separated from 
whole blood by centrifugation at 1110 g for 15 min at 4°C within the hour after extraction. 
Analytical methods 
Blood pressure was measured in the sitting position after 5 minutes rest. FBS, TC, TG, LDLc & HDLc were 
measured using an autoanalyzer (Hitachi 911 sunrise Corporate company Kobe, Japan) by a colorimetric method kit 
(ParsAzmun - Iran). CBC analysis was carried out by hematology analyzer Sysmex Kx-21N (Sysmex Corporation, 
Japan). 
 Peripheral blood mononuclear cell (PBMC) isolation 
Buffy coats were diluted 1:1 in BSS (Balanced salt solution); 4ml of diluted peripheral blood was layered on 
the 3ml of Ficoll–Hypaque solution (Amerhsam Biosciences, Piscataway, NJ). Density gradient centrifugation was 
carried out at 400 × g for 35 minutes. PBMC were harvested from the interface layer, washed twice with BSS. 
Harvested PBMCs were used to extract RNA directly. 
 RNA extraction and cDNA synthesis   
Total RNA was extracted from PBMCs using RN easy Mini Kit (Qiagen, Hilden, Germany). Quantity and 
purity of the extract were measured by Nanodrop (Epoch,BioTek) spectrophotometer and the ratio of A260/A280 
nm of all the samples were about 2. RNA integrity was assessed using 1% agarose gel, 1× TBE. RNA was judged 
suitable for gene expression only if samples exhibited intact bands corresponding to 18S and 28S ribosomal RNAs. 
Equal amounts of total RNA, approximately 0.5 micrograms, was reverse transcribed into single-stranded 
cDNA using QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany) following the kit manufacturer’s 
instructions. Briefly, one step gDNA wipeout in 42○C, then cDNA synthesis was performed at 42○C for 20 min, 
followed by RT inactivation at 95○C for 3 min. 
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 Quantitative real-time PCR  
PCR analyses were performed using C1000 Thermocycler and CFX96 real time system (BioRad) and 
QuantiFast SYBR Green PCR Kit (Qiagen, Hilden, Germany) in a final volume of 25 μl with 10 pmol of each 
primer. Each reaction was performed on 1 μl of 1:9 (v/v) dilution of the first cDNA strand.  
The reaction was incubated at 95°C for 5 min, followed by 40 cycles of 15s at 95°C, 30s at annealing 
temperature, 30s at 72°C and then fluorescence was measured. Primers, designed by software AlleleID7.6, were:  
IL-10-F (5'- GAGGACTTTAAGGGTTAC -3'),  
IL-10-R (5'- CTATGTAGTTGATGAAGATG -3'),  
LpR-F (5'- AGCCAATCTTCCTATTATC -3'), 
LpR -R (5'- CCTCATACATCTTCCATT -3'),  
βactin-F(5'- AAGATCAAGATCATTGCT -3'), 
βactin-R (5'- TAACGCAACTAAGTCATA -3').  
 
The gene numbers of different variants of LepR were NM_001198687, NM_001198688, NM_001198689, 
NM_001003679, NM_001003680, NM_002303 and the number belongs to IL-10 was NM_000572.  
Annealing temperature and PCR products were 48°C (292), 46.5°C (261) and 47.5°C (177) for IL-10, LepR 
and βactin, respectively. Specificity of PCR amplifications was verified by a melting curve program (70-95°C with a 
heating rate of 0.5°C/s and a continuous fluorescence measurement) and analyzed by electrophoresis on a 1% 
agarose gel, 1× TBE. Primer efficiencies were: IL-10, 101%; LpR, 106%; βactin, 98%. Expression values were 
obtained as relative expression of the target gene versus the constitutively expressed βactin gene (relative expression 
= 2-(Ct, Target gene-Ct, Reference gene)). 
 Statistical methods 
General values were expressed as means ± SD and gene expression level was reported as means ± SEM of 
three independent experiments. Values of p < 0.05 were considered significant. Results were analyzed using t-test 
for comparison between normal and MetS subjects and Mann–Whitney U-test for non-normal distribution. 
Spearman correlation coefficient was used for the determination of relations among variables. All statistical analyses 




 Characteristics of study population 
Patient‘s baseline characteristics are shown in Table 1. There were no differences in weight and height between 
two groups. All patients in MetS group and 40% of the subjects of non-MetS had waist circumferences more than 
90cm. The studied subjects were divided to 4 groups according to their BMI. These groups contained: normal 
weight (BMI=18.5-25), overweight (BMI=25-30), obese type1 (BMI=30-35) and obese type2 (BMI>35) as it is 
shown in Table 2. According to this classification, despite of existence more obese subjects (type1 & 2) in MetS 
group, no significant difference is discerned between MetS and non-MetS groups (P>0.05 by Pearson Chi-Square 
test) but when subjects classified into two groups (cut off is BMI=30) and comparing MetS in these groups, Fisher 
exact test showed significant difference (p=0.039) and we indicated the subjects that had BMI more than 30 are 
more susceptible to MetS than subjects with BMI less than 30 (OR = 2.931, 95% CI = 0.818–10.508).  
In an attempt to  investigate  any existing  correlation between stricken to MetS and family history,  the 
subjects were asked for any MetS parameters in their family,  both groups had approximately unique distribution of 
family history of disease and no remarkable difference was reported between these two groups (55 and 60 % in non-
MetS and MetS respectively).  
CBC measurement in all studied subjects did not show any significant differences in the mean RBC, WBC, 
neutrophil, lymphocyte, monocyte, eosinophil count, hematocrit percent,  and hemoglobin concentration between 
two groups (data not shown). 
 Metabolic syndrome components 
All subjects with MetS had waist circumferences more than 90cm as a diagnostic factor of MetS, frequency of 
other components in MetS group were: 75% high FBS, 65% hypertension, 60% hypertriglyceridemia, 45% low 
HDL. Correlation between MetS and MetS components is shown in the Table3. Results showed a relationship 
between MetS and total cholesterol (Table3). 
In MetS group waist circumference correlates with TC(r =0.503, P=0.024) and LDL-c(r =0.614, P=0.004) and 
in non-MetS with FBS. Although FBS did not correlate to any variable in MetS group, in non-MetS it correlated to 
BMI(r=0.526, P=0.021) and waist circumference (r=0.519, P=0.019). 
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 Gene expression in PBMC 
For each person and gene, ΔCT was computed and compared between the two groups. While there was a significant 
difference in the IL-10 expression between the two groups (11.39±1.18 in MetS group versus 9.97±1.22 in non-
MetS subjects p=0.001), also LepR expression was statistically different (13.85 ± 0.81 versus 14.76 ± 0.91 in MetS 
and non-MetS groups respectively). 
Gene expression (fold changes) in MetS group compared to non-MetS subjects was calculated by 2-ΔΔCT 
formula. In case of IL-10 MetS patients expressed 0.55±0.09 (mean ± SEM) fold compared to non-MetS subjects.  
The LepR expression change in MetS patients was significantly different from non-MetS (2.69±0.51 as mean ± 
SEM).  
Correlation study of IL-10 ΔCT showed reverse association with systolic pressure in MetS group (P=0.037, r = 
- 0.469) and with waist circumferences in all subjects participated in this study (P=0.01, r = 0.401). On the other 
hand LepR Delta CTs related to TC, LDLc and waist circumferences in MetS group (with P<0.05 and r = 0.445, r = 
0.452 and r = 0.494) and had connected to systolic pressure in all participants(P=0.027, r = - 0.349). 
 
Table1. Demographic data of the studied population 
 
Characteristic 
mean ± S.D  
P-value  MetS Non-MetS 
Age       (year) 53±10 47±6 NS 
BMI    (kg/m2) 29.7±4.3 27.3±3.5 NS 
WC      (cm) 101±7 91±6 0.000 
Sys.P  (mmHg) 139±26 114±13 0.000 
Dias.P (mmHg) 90±13 78±16 0.003 
FBS    (mg/dl) 123±38 96±6 0.000 
tChol  (mg/dl) 218±50 177±45 0.014 
TG      (mg/dl) 187±120 87±32 0.000 
HDLc  (mg/dl) 57±21 57±16 NS 
LDLc  (mg/dl) 127±39 111±38 NS 
MetS=metabolic syndrome, BMI= body mass index, WC= waist circumference 
Sys.P=systolic pressure, Dias.P= diastolic pressure, FBS= fasting blood sugar,  
TG= triglyceride, HDLc= high density lipoprotein cholesterol, 
LDLc= low density lipoprotein cholesterol, NS= non significant, 
 
Table2. Frequency of different degree of obesity in MetS and non-MetS groups 
Group normal weight Overweight obese type1 obese type2 
MetS (%) 10 50 20 20 
Non-MetS (%) 40 50 5 5 
 




WC FBS TG tChol HDLc* SysP DiasP 
r 0.692 0.691 0.576 0.394 0.022 0.593 0.469 
P value 0.000 0.000 0.000 0.012 0.894 0.000 0.002 
FBS= fasting blood sugar, TG= triglyceride, HDLc= high density lipoprotein cholesterol, WC = waist circumferences, tChol = total 
cholesterol, SysP = Systolic pressure, DiasP = Diastolic pressure 




As a report indicates fifty million Americans now have the diagnosis of metabolic syndrome [5], a group of 
life-shortening morbidities like type 2 diabetes and hypertriglyceridemia [27]. Many studies have demonstrated that 
inflammation is an important etiology of MetS [28] through its various effectors (eg, leptin, adiponectin, TNF-α, IL-
6, IL-10, etc) [29]. Report reviews have displayed the importance of obesity and insulin resistance in low-grade 
inflammation [30]. Recent studies concentrate on the role of inflammation on obesity and insulin resistance in MetS. 
Thus the genes involved in inflammation pathways have been evaluated for risk susceptibility and understanding of 
disease mechanism. Therefore in the present study, we quantified the relative gene expression of IL-10 and LepR in 
PBMCs in MetS subject and investigated correlation between these gene expression and other biochemical 
parameters.  
Leptin is a multifunctional cytoadipokine which involved in immune regulation through leptin receptor [19]. 
Leptin receptor belongs to the cytokine receptor class I superfamily [31]. Several isoforms (a-f) and a soluble form 
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(sOB-R) exist as a result of alternative mRNA splicing [32]. Our result shows 2 fold increases in gene expression of 
LepR in MetS compared to Non-MetS patients. Data relating to correlation of LepR with MetS and its risk factors 
are very limited. We found only one report that surveyed sOB-R and showed its concentrations were inversely 
correlated with BMI, waist circumference, systolic and diastolic blood pressure, triglycerides, and fasting glucose 
and positively with HDL cholesterol [16], therefore they considered sOB-R as a beneficial factor. Although we 
investigated all variants of LpR, we suggest negative effect of this protein, as LepR correlated with TC, LDLc and 
waist circumferences in MetS group in our study. 
The OB-Rb is the longest isoform that considered to be the functional receptor and contain intracellular motifs 
for the activation of janus kinase 2 (JAK2) and activator of transcription 3 (STAT3) followed by STAT3 
dimerization and nuclear translocation. Also leptin can activate PI3K as a direct result of binding to LpR [31-33]. 
Some researcher report that association of leptin and insulin resistance may be independent of fat mass, and 
suggest leptin resistance is considered as a component of the MetS [34]. In agreement with this suggestion, another 
paper show that inflammatory stimuli can induce elevated systemic leptin concentrations [35] and also leptin affects 
cytokine secretion patterns like increase of IL-6 secretion, while IL-6 is suggested to activate the NF-κB, STAT3 
and proinflammatory cascade [36]. Moreover leptin might regulate the inflammatory cell infiltration in visceral 
adipose tissue [15]. 
There are mentioned that leptin changes the cell cytokine secretion and facilitates inflammation. Also some 
reports show that leptin inhibits expression of IL-10 [37] or leads to down regulation of IL-10 in monocytic cell line 
U937 [25]. Against these data, other reports suggested highly significant positive association between leptin and IL-
10[25], therefore  we tried to study IL-10 gene expression plus LepR and found no relation between them. 
IL-10 is an anti-inflammatory cytokine and has multiple effects like inhibition of NFκB leading to suppressed 
cytokine production [39]. It seems that IL-10 is a regulator against the cascade of pro-inflammatory cytokines, 
including IL-6[21]. IL-10 expressed by a variety of cell types includes macrophages, dendritic cells, B cells, T cells 
and NK cells [40]. Also T cells are thought to be the main source of IL-10 in vivo [41]. It is known that there are 
clear associations between IL-10 and disease susceptibility [41]. Our result show 0.55 folds of IL-10 expression in 
MetS compare to Non-MetS and correlation of IL-10 ΔCT with waist circumferences and reverse association with 
systolic pressure, these findings are similar to other report that show more circulating level of IL-10 in obese subject 
[42]. Of course these reports showed weight loss causes increasing in this level [42]. The fact that number of 
macrophages in the visceral fat of subjects increased by obesity, justify this finding [43]. This report also shows that 
IL-10 level in MetS subject is less than controls. Other research shows that IL-10 production induced by LPS, is 
inhibited in MetS [24]. Nishida et al shows no significant differences in IL-10 level between MetS and controls, 
whereas they report lower level of adiponectin in MetS subjects. Also they indicated a correlation between IL-10 
and adiponectin in MetS subjects [44]. Thus some authors deduce that low IL-10 production capacity is associated 
with the metabolic syndrome [24]. 
Signaling of IL-10 receptor briefly includes of recruitment of Jak1 to receptor then phosphorylation of the 
receptor cytoplasmic tail, thus recruitment of STAT3 and its phosphorylation, next homodimerization and entry into 
the nucleus for transcription of IL-10-regulated genes [22]. However we could not find a correlation between LpR 
and IL-10 ΔCTs, consideration of some reports indicates leptin and IL-10 related to each other, therefore we suggest 
high leptin level and leptin resistance, accompany with increase LpR, may affect IL-10 expression that result 
unbalance between pro- and anti-inflammatory state and produce low grade inflammation that cause incorrect cycle 
and worsening condition [41]. 
As mentioned above LpR cause activation of JAK2 and STAT3 similar to IL-10 receptor, on the other hand 
STAT3 complex can trigger a negative feedback loop of IL-10 regulation [40]. 
Therefore possibly STAT3 is the key protein in induction and suppression of IL-10 expression.  Some 
researchers like Benkhart demonstrated a direct interaction of Stat3 with the human IL-10 promoter at –120 , and 
suggested an autoregulation mechanism of IL-10[45]. Another report indicated that Stat3 correspond to regulation of 
the IL10 gene via several different signaling pathways and have role in a feedback mechanism [41]. Of course major 
papers prove that IL-10 production is under tight genetic control, with heritability estimates as high as 75% [46]. 
One limitation of our report is the small sample size that could increase the risk of statistically false negative 
results (type II errors). Another limitation of this study was the fact that we intended the control group not to have 
any parameter of MetS but finding age-matched women without any MetS component was very difficult. Also it 
would be better to measure plasma level of leptin, sOB-R and IL-10 for more information and acquiring a better 
understanding of the involved mechanisms. Additional work and functional studies are needed to ascertain the 
biological importance and study the suggested mechanism reported in the current work. 
To our knowledge, this is the first research that investigated IL-10 & LepR expression in PBMCs of MetS subjects. 
In summary, we reported the increase LepR expression and decrease expression of IL-10 on PBMC of MetS 
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compared to control subjects. Study on a larger population, detecting synthesis of these proteins and cell culture 
study might reveal more details. 
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